Health CareHealth Care Equipment & Services
  • Price (EUR)17.50
  • Today's Change-0.05 / -0.28%
  • Shares traded72.77k
  • 1 Year change20.69%
  • Beta1.2647
Data delayed at least 15 minutes, as of Nov 15 2019 16:35 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.

  • Revenue in EUR (TTM)496.16m
  • Net income in EUR50.81m
  • Incorporated2007
  • Employees2.49k
  • Location
    Fagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
  • Phone+32 80012880
  • Fax+32 92162491
  • Websitehttps://fagron.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
FAGR:BRU since
Central De Drogas SA De CVAnnounced13 May 201913 May 2019Announced2.46%24.22m
Dr. Kulich Pharma sroDeal completed13 May 201913 May 2019Deal completed2.46%6.18m
Data delayed at least 15 minutes, as of Nov 15 2019 16:35 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
CellaVision AB39.69m9.79m646.95m136.0066.0721.0859.2816.304.374.3717.7313.711.103.217.743,614,556.0027.2224.0033.2130.0075.3971.8324.6721.683.68359.720.076855.2017.9415.1927.2036.1914.1924.57
Avon Rubber plc209.30m16.69m699.65m784.0041.626.9423.053.340.46420.46425.832.791.064.896.02--8.4213.2910.9217.9740.4438.167.9811.482.29--0.0012--8.347.52-27.785.753.00--
Revenio Group Oyj43.16m8.00m708.03m90.0083.4811.9573.3916.410.32050.32051.692.240.69228.447.19814,301.9012.8429.4015.0234.5251.1155.3118.5424.632.0161.210.3441172.0714.4317.8118.2922.4344.98-1.37
Biotage AB98.30m18.36m755.15m461.0041.079.2730.907.683.003.0016.1013.300.91152.674.692,586,059.0017.0315.1220.3618.3462.1158.6018.6815.671.79--0.162574.2521.7515.4220.8132.282.6720.11
Stratec SE214.25m13.53m799.08m1.28k59.155.2923.493.731.120.848317.8212.570.75412.825.50174,471.504.769.765.6411.9024.3932.136.3111.361.5914.980.404146.04-9.477.98-58.22-6.4214.016.45
Arjo AB (publ)822.92m32.00m989.92m6.18k33.151.898.,422,222.002.48--3.74--43.74--3.89--0.58535.420.372--6.88--150.85------
Paul Hartmann AG2.16bn73.68m1.09bn11.11k14.751.216.710.506720.7520.75607.41253.161.412.575.41195,635.705.146.507.008.8157.0156.903.644.321.2331.390.10730.052.943.38-10.516.604.244.19
Fagron NV496.16m50.81m1.26bn2.49k24.625.8716.842.550.71080.50966.942.980.68653.5311.07199,419.207.102.349.834.1544.9444.7810.344.110.77895.230.630238.418.806.60-8.130.5266-0.1623-30.06
Medacta Group SA290.86m32.83m1.46bn1.04k32.4013.8623.765.022.472.4719.435.77------327,047.20--------74.19--11.29--0.65596.750.6137--11.41--19.16------
Ypsomed Holding AG352.53m10.65m1.53bn1.70k143.224.4428.274.340.92450.924530.6029.830.66445.096.08240,452.602.019.972.9513.8223.9231.273.0210.940.5113--0.299828.63-2.6510.4315.5134.6133.3212.89
Data as of Nov 15 2019. Currency figures normalised to Fagron NV's reporting currency: Euro EUR

Institutional shareholders

29.69%Per cent of shares held by top holders
HolderShares% Held
NN Investment Partners BVas of 21 Oct 20194.70m6.55%
Capital Research & Management Co. (World Investors)as of 30 Sep 20192.63m3.66%
Capital International, Inc.as of 16 Sep 20192.41m3.35%
Capital Research & Management Co. (International Investors)as of 16 Sep 20192.28m3.18%
Evermore Global Advisors LLCas of 21 Oct 20192.20m3.07%
Carmignac Gestion SAas of 07 Nov 20192.15m2.99%
Norges Bank Investment Managementas of 08 Nov 20192.14m2.98%
The Vanguard Group, Inc.as of 31 Oct 20191.07m1.49%
Teslin Capital Management BVas of 30 Sep 2018884.06k1.23%
KBC Asset Management NVas of 30 Jun 2019853.87k1.19%
More ▼
Data from 31 Dec 2018 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.